

Table 2: Total Number of Prescriptions[†] Dispensed for Avandia[®] and Actos[®] Nationwide by Physician Specialty January 2003 – December 2005

	Jan 2003 - Dec 2003		Jan 2004 – Dec 2004		Jan 2005 - Dec 2005	
	N	%	N	%	N	%
Avandia[®]	7,811,000	100.0%	8,130,000	100.0%	10,385,000	100.0%
GP, FM, & DO*	3,043,000	39.0%	3,100,000	38.1%	4,134,000	39.8%
Internal Medicine	2,666,000	34.1%	2,685,000	33.0%	3,413,000	32.9%
Unspecified	712,000	9.1%	922,000	11.3%	993,000	9.6%
Endocrinologist	330,000	4.2%	315,000	3.9%	432,000	4.2%
Pediatricians	78,000	1.0%	83,000	1.0%	115,000	1.1%
All Others	985,000	12.6%	1,024,000	12.7%	1,299,000	12.5%
Avandamet[®]	935,000	100.0%	2,508,000	100.0%	1,895,000	100.0%
GP, FM, & DO*	381,000	40.8%	1,027,000	40.9%	810,000	42.8%
Internal Medicine	289,000	31.0%	747,000	29.8%	561,000	29.6%
Unspecified	79,000	8.4%	264,000	10.5%	169,000	8.9%
Endocrinologist	65,000	7.0%	152,000	6.0%	109,000	5.7%
Pediatricians	11,000	1.2%	29,000	1.2%	23,000	1.2%
All Others	109,000	11.6%	289,000	11.5%	223,000	11.8%

Verispan, LLC, January 2003 –December 2005, Data Extracted 02-2006 (File: VONA D040849 2-6-06 Rosiglitazone MD.qry, VONA D040849 2-27-06 Rosiglitazone MD detail.qry, VONA BPCA D040849 3-7-06 Avandamet MD detail.qry, and VONA BPCA D040849 3-7-06 Avandamet MD.qry)

* General Practice, Family Medicine & Osteopathic physicians

[†] Totals and subtotals may not sum exactly due to rounding